containing geranyl moieties incorporated in
their structures. Compounds with α-glucosidase inhibitory and
free radical scavenging activities are considered to be an
efficient way to treat degenerative diseases including type 2
diabetes,8 cancer,9 and viral infections.10 Moreover DNA is a
remarkable bioreceptor for a vast number of small molecules,
and it remains a major biological target for the design of
anticancer agents. DNA-intercalating agents have been studied
for several decades, and a few representatives (ellipticine,
rebeccamycin, anthracyclines, acridines, and anthraquinones)